Home
Diseases
Neuro-Degenerative Disease

Neuro-Degenerative Disease

Disease

Related News

Cortical Tri-Culture Model Validated for Neurodegenerative Drug Discovery

Apr 07, 2026

A cortical tri-culture model using human iPSC-derived neurons and astrocytes has been validated for neurodegenerative drug discovery and neurotoxicity screening. The model successfully identified compound modes of action in blinded testing, addressing a critical need for physiologically relevant cortical models. Neurodegenerative diseases affect approximately 15% of the global population, with prevalence expected to increase with aging populations.

Enveric Biosciences Reports Positive Preclinical Results for EB-003 and Corporate Updates

Mar 28, 2026

Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.

Advanced CTE Strongly Linked to Dementia in Major Brain Study

Mar 03, 2026

A Boston University study of 614 brains found that advanced chronic traumatic encephalopathy (CTE) from repeated head impacts significantly increases dementia risk, with stage IV CTE making individuals 4.5 times more likely to have dementia.

RNA-Targeting Small Molecules Gain Momentum as Drug Discovery Frontier

Feb 27, 2026

Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.

Drug Discovery Shifts to New Targets: RNA, Cell Surface Proteins, and Sequence-Based AI

Feb 20, 2026

Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07563777	100-Year Human Aging Study	RECRUITING
NCT07396818	Kamlanoflast In Amyotrophic Lateral Sclerosis	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07316764	Eccentric Cycling in Multiple Sclerosis Rehabilitation	NOT_YET_RECRUITING	NA
NCT07244900	Conventional Physical Therapy Action Observation Therapy on Freezing of Gait and Functional Mobility in Parkinson's Disease	COMPLETED	NA
NCT07163663	HIFT Training in People With Parkinson's Disease	COMPLETED	NA
NCT07126821	A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data	RECRUITING
NCT07087574	3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care	RECRUITING	NA
NCT06625710	Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects	COMPLETED	PHASE1
NCT06534177	Digital Diagnostics and Intervention Services for Parkinson's Disease	NOT_YET_RECRUITING
NCT06217237	Optimization and Harmonization of Advanced MRI Sequences	COMPLETED